Citable filing context
AMGN's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Amgen reported second quarter 2026 total revenues of $10.1 billion, a 10% increase year-over-year. |
| Jul 31, 2026 | other | Amgen identified a material cybersecurity incident involving unauthorized data exfiltration from third-party cloud environments. |
| May 20, 2026 | management_change | Amgen Inc. held its Annual Meeting, electing 12 directors and approving executive compensation. |
| Aug 4, 2026 | Guidance: capital_expenditures | not reported to 2.60 |
| Aug 4, 2026 | Guidance: gaap_eps | 15.80 to 17.08 |
| Aug 4, 2026 | Guidance: gaap_tax_rate | 14.50 to 16.00 |
| Aug 5, 2026 | mda_quarterly | Amgen reported strong financial performance for the first half of 2026, with total revenues reaching $18.67 billion, an 8% increase over the prior-year period. This growth was primarily driven by volume increases in key products, including Repatha, EVENITY, UPLIZNA, TEZSPIRE, and the newly launched IMDELLTRA/IMDYLLTRA. Conversely, the company faces significant headwinds from the Inflation Reduction Act (IRA), which has triggered Medicare price setting for ENBREL and Otezla, contributing to net selling price declines. Additionally, Prolia and XGEVA are experiencing accelerated sales erosion following the expiration of key patents. Operating expenses decreased by 7% for the six-month period, largely due to lower amortization of acquisition-related assets and the absence of the 2025 Otezla impairment charge. Amgen maintains a robust liquidity position with $14 billion in cash and cash equivalents, supported by a $4 billion revolving credit facility. However, the company remains embroiled in a major tax dispute with the IRS regarding profit allocations between U.S. and Puerto Rican entities for the 2010–2022 tax years. While Amgen contests these claims, an adverse outcome could result in material liabilities. Management continues to prioritize capital allocation toward R&D, particularly for the pipeline candidate MariTide, alongside ongoing dividend payments and share repurchases. |
| May 1, 2026 | mda_quarterly | Amgen's product sales and profitability face substantial pressure from evolving healthcare policies and market consolidation. The Inflation Reduction Act (IRA) significantly impacts products like ENBREL and Otezla through mandatory Medicare price setting, inflation-based rebates, and Part D redesign, with adverse effects projected to increase through the decade. State-level initiatives, such as Colorado's Prescription Drug Affordability Board (PDAB) setting a substantially lower Upper Payment Limit for ENBREL effective 2027, further intensify pricing challenges. Commercial payer consolidation, including large PBMs like CVS and United Health Group, increases negotiating leverage, leading to demands for deeper discounts and more restrictive formulary access for Amgen's medicines. Regulatory risks are also prominent. The FDA has proposed withdrawing TAVNEOS due to questions regarding study data and effectiveness, while accelerated approvals for products like LUMAKRAS face heightened scrutiny for confirmatory data. Global economic instability, geopolitical tensions, and supply chain disruptions, exacerbated by events like the Middle East conflict, increase operational costs and threaten international sales. Additionally, sophisticated and increasing cybersecurity threats, including those impacting third-party providers like Change Healthcare, pose ongoing risks to business operations and sensitive data integrity. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
AMGN company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.